Sidoti Csr Cuts Earnings Estimates for USANA Health Sciences

USANA Health Sciences, Inc. (NYSE:USNA) – Research analysts at Sidoti Csr lowered their Q3 2026 EPS estimates for USANA Health Sciences in a report released on Wednesday, February 11th. Sidoti Csr analyst A. Lebiedzinski now expects that the company will post earnings of $0.49 per share for the quarter, down from their previous estimate of $0.54. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q4 2026 earnings at $0.52 EPS, FY2026 earnings at $1.84 EPS, Q1 2027 earnings at $0.64 EPS, Q2 2027 earnings at $0.65 EPS and FY2027 earnings at $2.77 EPS.

Other research analysts also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, December 29th. Zacks Research lowered shares of USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, January 7th. Two investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus price target of $36.00.

USANA Health Sciences Trading Down 0.0%

NYSE:USNA opened at $20.95 on Monday. The firm’s 50 day moving average is $20.68 and its 200 day moving average is $23.75. USANA Health Sciences has a 12 month low of $18.48 and a 12 month high of $38.32. The stock has a market capitalization of $382.97 million, a PE ratio of 23.81, a price-to-earnings-growth ratio of 0.95 and a beta of 0.67.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in USNA. National Bank of Canada FI raised its position in shares of USANA Health Sciences by 166.6% in the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after buying an additional 1,201 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of USANA Health Sciences by 382.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after acquiring an additional 1,901 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of USANA Health Sciences by 1,354.3% during the 4th quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock valued at $76,000 after acquiring an additional 3,589 shares during the last quarter. CWM LLC grew its holdings in shares of USANA Health Sciences by 109.7% during the second quarter. CWM LLC now owns 2,762 shares of the company’s stock worth $84,000 after purchasing an additional 1,445 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of USANA Health Sciences by 52.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock worth $106,000 after purchasing an additional 1,327 shares during the last quarter. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.